Park Avenue Securities LLC Cuts Stake in Kenvue Inc. $KVUE

Park Avenue Securities LLC lessened its stake in shares of Kenvue Inc. (NYSE:KVUE) by 37.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 162,191 shares of the company’s stock after selling 96,606 shares during the period. Park Avenue Securities LLC’s holdings in Kenvue were worth $2,632,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Renaissance Capital LLC boosted its position in Kenvue by 8.3% during the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after purchasing an additional 48,267 shares during the period. Farther Finance Advisors LLC raised its position in shares of Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after purchasing an additional 16,164 shares during the period. Arlington Partners LLC purchased a new stake in shares of Kenvue during the 2nd quarter valued at approximately $2,110,000. AG2R LA Mondiale Gestion D Actifs bought a new position in Kenvue in the 1st quarter worth approximately $1,725,000. Finally, Cornell Pochily Investment Advisors Inc. grew its stake in Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after buying an additional 19,609 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Kenvue

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.68% of the stock is owned by insiders.

Kenvue Price Performance

Kenvue stock opened at $16.82 on Friday. The stock has a market cap of $32.22 billion, a price-to-earnings ratio of 22.42 and a beta of 0.60. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The business has a 50-day simple moving average of $16.90 and a 200 day simple moving average of $18.40. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. During the same quarter last year, the company posted $0.28 EPS. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.9%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Analysts Set New Price Targets

Several research firms have issued reports on KVUE. JPMorgan Chase & Co. dropped their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and decreased their price target for the company from $22.50 to $22.00 in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.